This article is more than 5 years old. Information may no longer be current.

First patient enrolled in EGP-437 trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The first patient has been enrolled in a phase 2b clinical study of EGP-437 for cataract surgery, according to an EyeGate Pharmaceuticals press release.

EGP-437 is a combination product candidate for the treatment of postoperative ocular inflammation and pain. The double-masked, randomized, placebo-controlled trial will enroll up to 100 patients and will be conducted at up to eight sites in the United States, the release said.

“This trial will allow us to better understand the clinical benefit patients are receiving from this therapy and to support its role in the management of pain and inflammation, common side effects following cataract surgery,” Stephen From, EyeGate president and CEO, said in the release.